HA
TLSI icon

HC Advisors’s TriSalus Life Sciences TLSI Stock Holding History

HC Advisors’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-101,736
Closed -$860K – 94
2023
Q4 		$860K Buy
+101,736
New +$524K 0.48% 40

Other funds holding TLSI

DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CWM
Connecticut Wealth Management Farmington, Connecticut $2.39B AUM 17.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LNWWM
Laird Norton Wetherby Wealth Management San Francisco, California $2.45B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AC
Anson Capital Tyrone, Georgia $146M AUM 18.69% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HC Advisors's TLSI Position: Q1 2024 in Review

HC Advisors sold out of TriSalus Life Sciences (TLSI) in Q1 2024, closing a stake of 101,736 shares — an estimated $860K sold.

HC Advisors first reported a position in TLSI in Q4 2023 and held it in 1 quarter. The position peaked at $860K in Q4 2023. 26 funds tracked by Wall St. Rank hold TLSI as of Q1 2024.

  • HC Advisors reported no remaining TriSalus Life Sciences position as of Q1 2024 after selling out during the quarter.
  • HC Advisors sold 101,736 TriSalus Life Sciences shares in Q1 2024, an estimated $860K.
  • HC Advisors first reported a position in TriSalus Life Sciences in Q4 2023 and held it in 1 quarter.
  • HC Advisors's TriSalus Life Sciences position peaked at $860K in Q4 2023.
  • 26 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q1 2024.

Based on HC Advisors's 13F filing for Q1 2024, filed 14 May 2024.